An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Spectrum Pharmaceuticals (NASDAQ: SPPI) has announced its participation in the upcoming H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022, in Miami Beach and virtually. A presentation will be accessible on the company's Investor Relations webpage starting May 24, 2022, at 7:00 a.m. ET. The company specializes in targeted oncology therapies and boasts a robust pipeline aimed at addressing unmet medical needs. Spectrum emphasizes its commitment to developing and commercializing innovative treatments in the biopharmaceutical sector.
Positive
None.
Negative
None.
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26, 2022. A presentation will be available on the Investor Relations section of the company’s website at http://investor.sppirx.com/events-and-presentations beginning on May 24, 2022 at 7:00 a.m. ET / 4:00 a.m. PT.
AboutSpectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Notice Regarding Forward-looking Statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
When will Spectrum Pharmaceuticals present at the H.C. Wainwright Global Investment Conference?
Spectrum Pharmaceuticals will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 a.m. ET.
Where is the H.C. Wainwright Global Investment Conference being held?
The H.C. Wainwright Global Investment Conference will take place in Miami Beach and also virtually from May 23-26, 2022.
What is the focus of Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals focuses on novel and targeted oncology therapies, aiming to address areas of unmet medical need.
How can I access the presentation by Spectrum Pharmaceuticals?
The presentation by Spectrum Pharmaceuticals will be available on the Investor Relations section of their website at http://investor.sppirx.com/events-and-presentations.
